Search Results
- < Prev
1 of 1
- Next >
News Releases
-
May 15, 2013, 18:01 ET
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug Administration (FDA) approved product Xofigo® (radium Ra...
More news about: Bayer HealthCare Pharmaceuticals Inc. , American Society of Clinical Oncology (ASCO)
-
May 15, 2013, 11:40 ET
Bayer Receives U.S. FDA Approval for Xofigo® (radium Ra 223 dichloride) Injection as a New Treatment for Castration-Resistant Prostate Cancer with Bone Metastases
Intended for U.S. Media Only -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved Xofigo® (radium Ra 223 dichloride) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral...
More news about: Bayer HealthCare Pharmaceuticals Inc.
-
May 15, 2013, 02:30 ET
Bayer Initiates Phase III Trial of Stivarga® (regorafenib) Tablets in Patients with Advanced Liver Cancer
Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga® (regorafenib) tablets for the treatment of patients with...
More news about: Bayer HealthCare Pharmaceuticals Inc. , Bayer HealthCare LLC , Bayer AG
-
May 08, 2013, 08:00 ET
Bayer to Present Data on Investigational Pulmonary Hypertension Compound Riociguat at ATS 2013
Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scientific forum at the American Thoracic Society (ATS) International Conference May 17 – 22, in Philadelphia, PA. "We are pleased that...
More news about: Bayer HealthCare Pharmaceuticals Inc.
-
Apr 29, 2013, 02:30 ET
Bayer to acquire Conceptus, Inc.
Bayer intends to broaden its portfolio in the field of contraception. Thus, Bayer HealthCare LLC has signed a merger agreement with Conceptus, Inc. (NASDAQ:CPTS), the California-based developer of the Essure® procedure, the leading non-surgical permanent birth control method, which is...
More news about: Bayer HealthCare Pharmaceuticals Inc. , Conceptus, Inc.
-
Apr 16, 2013, 16:15 ET
Actavis Confirms Favorable Ruling in Generic Yaz® Patent Suit
Actavis, Inc. (NYSE: ACT) today announced that it has re-launched Vestura™ (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer HealthCare Pharmaceuticals Inc.'s Yaz® oral contraceptive product, following a ruling from the United States Court of Appeals for...
More news about: Actavis, Inc. , Bayer HealthCare Pharmaceuticals Inc.
-
Apr 16, 2013, 05:00 ET
Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
Bayer HealthCare Pharmaceuticals Inc. announced today that patient enrollment is underway in its global Phase III trial program to evaluate the efficacy and safety of adjunctive aerosolized BAY41-6551 versus aerosolized placebo in the treatment of intubated and mechanically ventilated...
More news about: Bayer HealthCare Pharmaceuticals Inc. , Nektar Therapeutics
- < Prev
1 of 1
- Next >
Modify your Search
 |
Quickly search for PR Newswire releases by adding our plugin to your browser search |